Yarrow Bioscience, Inc. — Form 8-K
Filed September 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 28/100
What the filing says
Yarrow Bioscience (formerly VYNE Therapeutics) completed a reverse merger in July 2026 and raised $200M in financing (including $100M pre-closing). The company in-licensed YB-101, an anti-TSHR antibody, from GenSci in December 2025 for $70M upfront plus up to $1.295B in milestones. Yarrow initiated a Phase 2a/2b trial in Graves' disease in June 2026 and received FDA Fast Track designation in May 2026; Phase 2a data expected in H2 2027. Cash balance was $108.8M as of August 31, 2026, providing runway into 2028.
Why this rating
Early-stage biotech with unproven clinical asset; $200M raised is major but only ~6.3x company market cap; one Phase 2 readout pending mid-2027.
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.